Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

HONG KONG, Jul 21, 2022 – (ACN Newswire) – On July 21st, 2022, Lunit, a leading global AI-based cancer solutions provider invested by Legend Capital, was successfully listed on the KOSDAQ market.

Founded in 2013, Lunit successfully established itself as the world's top-notch artificial intelligence technology solution provider, mainly focusing on developing medical software to assist physicians in the realm of tumor diagnosis and treatment. Lunit's flagship products are Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT is an AI-powered image screening solution, that detects and classifies chest abnormalities and breast cancer. Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients.

Legend Capital led Lunit's series B investment round in June 2018 and continued to support Lunit's global business expansion via three additional follow-on investments in 2019 and 2021. For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth. Lunit's annual revenue grew by over 460% in 2021 since its initial product commercialization in 2019. As of now, Lunit's image diagnostic products have been certified by 42 countries/regions, including FDA, CE, and KFDA. The company will keep expanding into the global market through cooperation with international giants like GE Healthcare, Fujifilm, and Philips, etc. Legend Capital will continue to assist Lunit in finding untapped business opportunities in China by building up branding and introducing rich portfolio resources for cooperation.

Brandon Suh, CEO of Lunit, said: "Lunit's target market for cancer detection and diagnosis is worth 110 billion US dollars (of which the United States accounts for ~USD 45bn and the rest USD 65bn). Lunit's AI medical image analysis technology has significant advantages over traditional technology, and our accurate and efficient solutions have been appreciated by global medical institutions. Lunit's ongoing global expansion can be attributed to the support from our existing partners, Legend Capital has been one of Lunit's key partners in helping us grow our China business by introducing reliable local partners. Legend Capital has been and will continue to be Lunit's strategic global partner going forward."

"We like to invest in companies that have a global vision, world-leading technology, and global expansion capabilities. We were very impressed with Lunit's ambition to go global at our initial investment," said Joon-Sung Park, Managing Director of Legend Capital. "With the world's top-notch AI medical imaging technology, Lunit INSIGHT can significantly improve abnormalities detection and early-diagnosis rate, remarkably enhancing the efficiency of cancer diagnosis and treatment. Lunit has built a professional team with technology experts and medical professionals. The six co-founders are all graduates of the Korea Advanced Institute of Science and Technology (KAIST), the nation's first public, research-oriented science and engineering institution. With a commitment to empowering the medical industry by AI technology, Lunit has also hired 12 full-time doctors with an in-depth understanding of medical service. It has provided AI healthcare services to approximately 600 medical institutions in over 40 countries, and has signed an exclusive business contract with Guardant Health, the world's largest liquid biopsy diagnostic company, to collaborate on cancer drug development."

At present, "Lunit INSIGHT CXR Triage" and "Lunit INSIGHT MMG" have been certified by the U.S. Food and Drug Administration (FDA) by the end of 2021, and Lunit will continue to expand the global market by obtaining Medical Device Single Audit Program (MDSAP) certification in the US, Canada, Japan, Australia and Brazil, etc. Legend Capital has invested heavily in companies that integrate technology and the medical industry and has kept betting on AI medical sectors. In addition to Lunit, Legend Capital has also invested in AI medical companies such as Xbiome, an AI microbiome drug development company; StoneWise, an AI drug R&D platform; Deepwise, an AI medical imaging company; BioMap, a biocomputing platform; Deep Informatics ++, an AI medical pathology diagnosis company; and Unimed, an AI brain diagnosis and treatment platform.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally

ADELAIDE, AUS, Jul 20, 2022 – (ACN Newswire) – TrialWire(TM) Technology Platform, the most secure and rapid digital patient recruitment Platform for trial rescue, today announced the rollout of the proprietary SMS/Text patient contact system across all studies globally.

The SMS/Text patient contact system is a world first in speed, security, and compliance for study coordinators contacting patients to discuss their study application and site bookings.

It is primarily designed to speed up the contact process which is typically delayed using phone or email. Up to 50% of patients can be lost due to contact failure because they often don't answer an unknown number call from a site. In addition, study coordinators often can't afford the time to call more than 3-4 times in the hope of connecting with the patient.

TrialWire has found from patient responses that 92% want to be contacted by SMS/Text so this was a driving force behind the development and rollout of the service. This includes studies for older people.

The SMS/Text system can support all languages and keeps a record in the study coordinator's Dashboard of all conversations.

Most study coordinators are using the contact system to arrange then confirm times for screening calls, or site screening visits.

TrialWire recruitment can start in under 24-hours because the Platform doesn't require approvals.

The TrialWire Technology Platform includes:
– Dedicated secure dashboards for each Study Coordinator where they can review patient details and medical information
– Multiple dashboards per site so all Study Coordinators can see real-time progress
– Dashboards for sponsors and CROs where they can see de-identified referral status information
– Secure SMS system inside their dashboards for instant communications with the patient – book calls and screening visits
– Automated AI-Match and algorithm-driven "find and screen" patients process
– Minute-by-minute metrics for Study Coordinators showing numbers referred, contacted, screened, and enrolled at their site
– Minute-by-minute metrics for sponsors and CROs showing numbers referred, contacted, screened, and enrolled – across all sites on a study
– HIPAA compliance and all patient privacy security
– Built on the Salesforce Health Cloud
– Unlimited number of sites globally
– Available in all languages

With more than 80% of clinical trials failing to recruit patients on time, and 30% of research sites not able to meet enrollment goals – 10% of sites don't enroll any patients – TrialWire offers peace of mind for sponsors and their CROs.

TrialWire is ideal for sponsors and CROs wanting to avoid extended recruitment delays.

Request more information here – starts in 24 hours https://trial-wire.com/contact/
Learn more here https://www.trial-wire.com/

About TrialWire www.trial-wire.com

TrialWire is a privately held technology company that leverages 25 years of experience in the clinical trial patient recruitment sector. TrialWire, which is solving the most serious problem in the drug development sector, has a recent valuation of USD$27m.

Its mission is to end the patient recruitment crisis delaying the development of new therapies which is costing drug companies billions of dollars a day due to problems finding the right people quickly and enrolling them at the site level.

The TrialWire Platform is the most secure service (powered by Salesforce Health Cloud) that uses advanced algorithms to find the right people who are online that might be suitable for studies available on the Platform. They are invited into the Platform and taken through the AI-Match screener to determine an exact match to a study – site-based or remote/virtual. No account sign-up is required to find and apply for a study. The Platform ingests study data from approved trial registries like ClinicalTrials.Gov. It uses advanced online algorithms to find patient/trial matches based on detailed demographic and location profiles.

Key to the TrialWire success is that it finds motivated people who are actively online trying to find out more about their conditions. They can be connected to a site in under 2 minutes. These people have high retention rates. Unlike all other digital recruitment firms, TrialWire does NOT keep patient details once a study is completed – no databases so no potential privacy breaches. Sponsors are not paying for database building where patients are sent to other studies.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide

PETALING JAYA, Malaysia, Jul 20, 2022 – (ACN Newswire) – UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level.

Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]

Under this agreement, a virtual genome service centre will be developed on iMedic platform enabling the genomic testing services of MGRC to be made available to the hospitals and clinics (B2B), widening its market access not just in Malaysia, but globally. Additionally, the genomic testing services will also be made available to patients directly (B2C). Patients' genomic data from their test results will be integrated into Electronic Medical Records (EMR) making it accessible by doctors and patients in the process of consultation and management, resulting in improved accuracy in diagnosis and treatment.

UCrest is the leading technology provider of digital health platform with offices in Malaysia, Singapore, China and Taiwan providing access to thousands of doctors, including many from the leading hospitals in the United States and China, to provide online consultation and management of patients anywhere in the globe.

Malaysian Genomics is a leading genomics and biopharmaceutical company in ASEAN for genome sequencing, bioinformatics analysis, and genetic screening, and various types of immunotherapy including CAR T-Cell therapy for the treatment of certain cancers.

The global genomics market size was valued at US$20.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.35% from 2021 to 2028. The Asia Pacific genome sequencing market will grow by 15.6% annually over 2022-2030 due to growing government funding initiatives in genomics projects related to cancer treatment and the utilization of genomics in personalized medicine targeting chronic disease prevention and management.

Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "We are looking forward to working with UCrest as its iMedic platform will provide us an opportunity to reach out to markets beyond Malaysia. The platform will also enable us to strengthen our B2B and B2C channels. This collaboration can play an important role in providing physicians with easy access to the latest in genetic screening, in support of enhancing their medical practice and improving patient outcomes."

"This partnership with Malaysian Genomics allows us to enhance our vision of integrating preventive and precision medicine into iMedic where genome data will empower the patients to better prevent and manage the chronic diseases with the online consultation of doctors," said Mr. Eg Kah Yee, Chief Executive Officer of UCrest. "Cancer, Cardiovascular Diseases (CVD), diabetic, asthma, sleep apnea and many other chronic diseases can be prevented, managed or treated more effectively with the addition of the genome services," he added.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
UCrest Berhad: 0005 [BURSA: UC] https://www.ucrest.net/

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years

Cambridge, MA, Jul 19, 2022 – (ACN Newswire) – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. Until now, children under six were the only age group not eligible for vaccination against COVID-19 in Australia.

"We are pleased that our vaccine for children under six years of age has received provisional approval by the TGA," said Michael Azrak, General Manager of Moderna for Australia and New Zealand. "The continued evolution of COVID-19 represents an emergent threat to global public health, including young children. Since the onset of the pandemic, we have worked with a deep sense of responsibility to deliver on the promise of mRNA science to all Australians. The approval from TGA helps extend an opportunity to all parents and caregivers in Australia to protect their young children against SARS-COV-2."

Positive interim results from the Phase 2/3 KidCOVE study, announced on March 23, 2022, showed a robust neutralizing antibody response in the 6-month to 5 years of age group after a two-dose primary series of mRNA-1273, along with a favorable safety profile. The antibody titers in the pre-specified 6 month to 23 month and 2 years to 5 years of age sub-groups met the statistical criteria for similarity to the adults in the COVE study, which satisfied the primary objective of the study. Preliminary efficacy analysis on PCR-confirmed cases collected during the Omicron wave showed similar efficacy estimates against Omicron in the 6-month to 5 years of age group to those in adults after two doses of mRNA-1273.

The KidCOVE study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The ClinicalTrials.gov identifier is NCT04796896.

Moderna is committed to supporting the Australian Government on the COVID-19 program implementation in children aged 6 months to five years upon receiving a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI).

The TGA previously approved the use of Moderna's mRNA COVID-19 vaccine, Spikevax (elasomeran mRNA vaccine), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six years or over.

Authorized Use

Therapeutic Goods Administration has provisionally approved the use of Moderna's mRNA COVID-19 vaccine, Spikevax (elasomeran mRNA vaccine), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This post contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the development of the Company's COVID-19 Vaccine (mRNA-1273, or Spikevax); the approval of the vaccine in children ages 6 months to 5 years by the Therapeutic Goods Administration; and the safety, efficacy, and tolerability of the vaccine in children ages 6 months to 5 years of age. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

Moderna Contacts

Media:
Luke Mircea-Willats
Director, Media Relations & Communications
Luke.mirceawillats@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Novotech and Endpoints Present “Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T”

SYDNEY, Jul 18, 2022 – (ACN Newswire) – Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China – the current landscape and future opportunities.

China now represents 60% of clinical development in CAR-T therapy development globally. This webinar will cover learnings to date and future opportunities.

Specific areas covered include:
– The current landscape for biotech CAR-T therapy research in China
– CAR-T clinical development in China: key areas of focus
– Potential opportunities related to universal CAR-T cell therapy development
– The challenges of allogeneic CAR-T cell therapy

Register here: https://webinars.endpts.com/evolution-of-cell-gene-therapy-in-china-the-case-for-universal-car-t/

Webinar Date:
– July 19, 2022
– 1:00 pm – 2:00 pm EDT

Moderator:
– Arsalan Arif, Founder and Publisher Endpoints News

Presenters:
– Dr. Jie Cheng, Chief Medical Officer Bioheng
– Dr. Vivian Gu, Vice President, Clinical Development & Regulatory, CMO, Novotech China
– Dr Kai Xue, Associate Professor, Department of Haematology, Ruijin Hospital, Shanghai, China

According to Global Data: "Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites."

Novotech CEO Dr. John Moller said: "The Asia-Pacific is the fastest-growing clinical trial destination for biotechs, with China being the leading location for new trials followed by the US. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, also offers its biotech clients clinical services in the US to support later phase global studies. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

About Novotech

Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

TrialWire Technology Platform Announces Success-based Patient Recruitment Plan

ADELAIDE, AUS, Jul 18, 2022 – (ACN Newswire) – TrialWire(TM) Technology Platform, the fastest and most secure digital patient recruitment Platform for trial rescue powered by Salesforce Health Cloud, today announced the launch of its success-based recruitment plan.

With clinical budgets and investment funds tightening globally, TrialWire is supporting the biotech drug development sector with a success-based patient recruitment solution.

Designed to help manage budgets, the Success-based Plan means sponsors only pay when a person is actually enrolled in a study.

In addition, recruitment can start in under 24-hours because the Platform isn't subject to the normal lengthy approval processes.

The Success-based Plan includes all the normal benefits from the TrialWire(TM) Technology Platform:
– Dedicated secure dashboards for each Study Coordinator where they can review patient details and medical information
– Multiple dashboards per site so all Study Coordinators can see real-time progress
– Dashboards for sponsors and CROs where they can see de-identified referral status information
– Secure SMS system inside their dashboards for instant communications with the patient – book calls and screening visits
– Automated AI-Match and algorithm-driven "find and screen" patients process
– Minute-by-minute metrics for Study Coordinators showing numbers referred, contacted, screened, and enrolled at their site
– Minute-by-minute metrics for sponsors and CROs showing numbers referred, contacted, screened, and enrolled – across all sites on a study
– HIPAA compliance and all patient privacy security
– Built on the Salesforce Health Cloud
– Unlimited number of sites globally
– Available in all languages

With more than 80% of clinical trials failing to recruit patients on time, and 30% of research sites not able to meet enrollment goals – 10% of sites don't enroll any patients – TrialWire(TM) offers peace of mind for sponsors and their CROs.

TrialWire(TM) is ideal for sponsors and CROs wanting to avoid extended recruitment delays.

Request more information here https://trial-wire.com/contact/
Learn more here https://www.trial-wire.com/

About TrialWire(TM) www.trial-wire.com

TrialWire(TM) is a privately held technology company that leverages 25 years of experience in the clinical trial patient recruitment sector. TrialWire(TM), which is solving the most serious problem in the drug development sector, has a recent valuation of USD$27m.

Its mission is to end the patient recruitment crisis delaying the development of new therapies which is costing drug companies billions of dollars a day due to problems finding the right people quickly and enrolling them at the site level.

The TrialWire(TM) Platform is the most secure service (powered by Salesforce Health Cloud) that uses advanced algorithms to find the right people who are online that might be suitable for studies available on the Platform. They are invited into the Platform and taken through the AI-Match screener to determine an exact match to a study – site-based or remote/virtual. No account sign-up is required to find and apply for a study. The Platform ingests study data from approved trial registries like ClinicalTrials.Gov. It uses advanced online algorithms to find patient/trial matches based on detailed demographic and location profiles.

Key to the TrialWire(TM) success is that it finds motivated people who are actively online trying to find out more about their conditions. They can be connected to a site in under 2 minutes. These people have high retention rates. Unlike all other digital recruitment firms, TrialWire(TM) does NOT keep patient details once a study is completed – no databases so no potential privacy breaches. Sponsors are not paying for database building where patients are sent to other studies.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

EC Healthcare Provides Healthcare Services for Signature and Prestige Banking Customers of Hang Seng Bank

HONG KONG, Jul 18, 2022 – (ACN Newswire) – EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the Group will provide diversified healthcare services for Signature and Prestige Banking customers of Hang Seng Bank via the brands under the Group, including New York Medical Group, Hair Forest, DR REBORN and ATO HAIR CLUB.

As the leading healthcare services provider, EC Healthcare is committed to providing professional, premium and diversified medical healthcare services covering 29 medical disciplines and to bringing health, beauty and happiness to the world. EC Healthcare will safeguard the health of banking customers in line with the client-centric core value, and provide comprehensive healthcare, aesthetic and beauty and kids well-being and healthcare services for them and their children. The promotion period started from 1 July 2022 and will end till 30 June 2023.

*Please refer to the [Terms and Conditions] on the Hang Seng website for detailed information.

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, focusing on preventive and precision medicine, the leverage investment in IT, brand, service and corporate culture aims build a diversified enclosed healthcare ecosystem, bringing health, beauty, and happiness to everyone. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic Premier Medical Centre, Specialist Central and New Medical Centre, a paediatric centre PrimeCare, a gynaecology specialist Zenith Medical Centre and Paternal Diagnosis Centre, PathLab Medical Laboratories, Ophthalmology Center Vivid Eye, and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Malaysian Genomics Appoints New Chairman

PETALING JAYA, Malaysia, Jul 15, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Company has appointed Dato' Seri Dr Chen Chaw Min as the Independent Non-Executive Chairman of the Board of Directors.

Dato' Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics

Dato' Alvin Joseph, Executive Director of Malaysian Genomics

The appointment is effective 15 July 2022, following the resignation of Tan Sri Ahmad bin Mohd Don on 12 July 2022.

Dato' Seri Dr Chen, who was appointed to the Board on 3 August 2021, was with the Malaysian civil service from 1988 until his retirement in February 2021. He was the Secretary-General of the Ministry of Health (MOH) from July 2015 until his retirement and has also served in various capacities in the Ministry of Finance (MOF) from 1990 until 2014.

Dato' Seri Dr. Chen said, "I feel privileged to take on this role at such an exciting time for Malaysian Genomics. The Group is currently expanding downstream to healthcare services and pioneering holistic care which will benefit many for the years to come, I hope that my experience in both MOH and MOF will be able to add knowledge and insights to support the Company's growth."

Dato' Alvin Joseph, Executive Director of Malaysian Genomics said, "We welcome Dato' Seri Chen to the Board of Malaysian Genomics as Chairman of the Board and look forward to working with him in ensuring proper governance in our business operations. His extensive experience in the civil service and in particular in MOH will be invaluable to us."

"We would like to extend our thanks to Tan Sri Ahmad bin Mohd Don for his invaluable contributions and guidance to the Board in executing their duties. We wish him all the best in his future endeavours."

Dato' Seri Dr Chen obtained a doctorate in finance from Universiti Putra Malaysia in 2005. He received an MBA (Finance) from University of Illinois in 1997 and a Bachelor in Surveying from University of Technology, Malaysia, in 1985.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Malaysian Genomics Appoints New Chairman

Dato' Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics

Dato' Alvin Joseph, Executive Director of Malaysian Genomics

Basecare Medical and Haier Biomedical Join Forces to Build Cryopreservation Solutions for Assisted Reproduction

Qingdao, Shandong, China, Jul 14, 2022 – (ACN Newswire) – Suzhou Basecare Medical Corporation Limited ("Basecare Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 2170) officially announced that the Company entered into a strategic collaboration framework agreement with Qingdao Haier Biomedical Co., Ltd. (hereinafter referred to as "Haier Biomedical"). According to the agreement, Basecare Medicaland Haier Biomedical will carry out collaborative R&D in cryogenic refrigeration of the assisted reproduction sector and jointly offer cryopreservation solutions for the assisted reproduction sector, which is another in-depth business collaboration following the capital collaboration between Basecare Medical and Haier Venture Capital FOF. Dr. LIU Zhanjie, founder and general manager of Haier Biomedical, Mr.LIU Dong, general manager of Haier Venture Capital Qianfeng FOF, and Dr. LIANG Bo, founder of Basecare Medical, attended the signing ceremony.

Signing Ceremony for Strategic Cooperation

Embryo laboratory, andrology laboratory, and cryogenic storage laboratory are essential components in assisted reproduction. Cryogenic freezing technology, as an indispensable and important technology in the implementation of assisted reproduction, has been widely used in the field of assisted reproduction, providing guarantee and hope for the needy population to achieve reproductive needs and reproductive health. The 2018 "Chinese Expert Consensus on the Time Limit of Frozen Embryo Preservation" pointed out that cryopreserved embryos should be used within 5 years, and the longest preservation and clinical use period of couples planning to reproduce should not exceed 10 years, which means large amounts of storage resources will be increasingly invested in assisted reproduction centers, including storage containers, storage space & management, and maintenance work, etc. With the increase in the number of infertile and advanced mothers, the demand gap for fertility preservation continues to expand, and the market potential is vast.

Focus on fertility preservation, build cryopreservation solutions in the field of assisted reproduction
Haier Biomedical, the first company in Qingdao listed on the Science and Technology Innovation Board, was founded to engage in the R&D, manufacturing and sales of biomedical cryopreservation equipment. Haier Biomedical has comprehensively promoted the integration and innovation of IoT technology and low-temperature storage technology. It combines IoT software and hardware based on network communication and radio frequency identification technology with self-developed low-temperature storage products. Haier Biomedical updated traditional storage devices to the IoT solution, which effectively meets the needs of users such as clinical blood use, vaccination, and biobank application building the leading IoT technology ecosystem. Haier Biomedical took the lead in breaking the foreign monopoly, independently developed and mastered the core technology of ultra-low temperature refrigeration, and has become the unique service provider of biomedical cryopreservation equipment covering a full temperature range from -196 degree celsius to 8 degree celsius worldwide.

Basecare Medical is a third-generation IVF clinical solution provider in assisted reproduction in China and the first HKEx-listed IVD company in assisted reproduction. Basecare Medical has been adhering to the concept of " making innovative products ", adhering to the industrialization road of R&D, registration and certification. Basecare Medical has initiated the R&D of embryo intelligent storage equipment and management system. The independent developed domestic intelligent liquid nitrogen tank (BCT38A) and ultra-low temperature storage instrument (BSG800A), registration certificates are expected to be obtained in 2022 and 2023 respectively, are providing guarantee for the safety of fertility preservation and the scientific nature of experimental management. The intelligent liquid nitrogen tank (BCT38A) will become the first liquid nitrogen tank product in China to obtain the second-class medical device registration certificate.

In this strategic collaboration, the two parties will integrate their respective resource advantages such as products and channels, and jointly build a cryopreservation solution in assisted reproduction sector from market promotion, technical support, collaborative R&D, to registration and certification, promoting the development of fertility preservation related application scenarios. In addition, the new resource-sharing model will facilitate the development of the assisted reproductive industry, delivering good products and technologies to enter clinical applications quickly and effectively, so as to benefit more patients.

About Suzhou Basecare Medical Corporation Limited

Suzhou Basecare Medical Corporation Limited is a third-generation IVF clinical solution provider in the field of assisted reproduction in China and the first listed IVD company in the field of assisted reproduction (stock code: 2170.HK). It is committed to the product R&D and clinical application of high-throughput sequencing technology in the field of reproductive health. Basecare has been adhering to the concept of "innovative products", adhering to the industrialization road of R&D, registration and sales, and has a product pipeline covering embryo testing, andrology testing and fertility preservation. The PGT-A (pre-implantation chromosome aneuploidy testing) kit independently developed by the company has won China's first "special approval for innovative medical devices" green channel. It is the first third-generation tube testing product in China to obtain the registration certificate of Class III medical devices, opening the "certificate era" of genetic testing kits in the field of assisted reproduction in China.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com